Abstract: 221
Type: Educational Session
Abstract Category: N/A
MS diagnostic criteria have evolved over time. The 2017 updates to the McDonald criteria allow the inclusion of symptomatic and asymptomatic lesions on MRI to determine dissemination in space (DIS) or time (DIT). Furthermore, in addition to juxtacortical lesions, cortical lesions can now be used to fulfil the MRI criteria. An important change to the criteria is the return of cerebrospinal fluid (CSF) data: in patients with a typical CIS and clinical or MRI criteria for DIS but not fulfilling DIT, demonstration of CSF oligoclonal bands now permits the diagnosis of MS. The impact of these changes in clinical practice has not been fully established. It is important to identify the proportion of patients fulfilling exclusively the 2017 McDonald criteria in clinical practice and the proportion of these patients with a confirmed diagnosis on follow-up. Application of this new set of criteria in different cohorts will be discussed. Clinical cases illustrating the implementation of the new criteria will be presented.
Disclosure: M Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, , Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal-ETC
Abstract: 221
Type: Educational Session
Abstract Category: N/A
MS diagnostic criteria have evolved over time. The 2017 updates to the McDonald criteria allow the inclusion of symptomatic and asymptomatic lesions on MRI to determine dissemination in space (DIS) or time (DIT). Furthermore, in addition to juxtacortical lesions, cortical lesions can now be used to fulfil the MRI criteria. An important change to the criteria is the return of cerebrospinal fluid (CSF) data: in patients with a typical CIS and clinical or MRI criteria for DIS but not fulfilling DIT, demonstration of CSF oligoclonal bands now permits the diagnosis of MS. The impact of these changes in clinical practice has not been fully established. It is important to identify the proportion of patients fulfilling exclusively the 2017 McDonald criteria in clinical practice and the proportion of these patients with a confirmed diagnosis on follow-up. Application of this new set of criteria in different cohorts will be discussed. Clinical cases illustrating the implementation of the new criteria will be presented.
Disclosure: M Tintore has received compensation for consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, , Biogen-Idec, Genzyme, Merck-Serono, Novartis, Roche, Sanofi-Aventis, and Teva Pharmaceuticals. MT is co-editor of Multiple Sclerosis Journal-ETC